1. A Reappraisal of Economic Evaluation of Pharmaceuticals

   • Michael F. Drummond

   Current Opinion 16 September 2012 Pages: 1 - 9

2. The Role of Pharmacoeconomic Evaluations in Disease Management

   • Kenneth Chang
   • David Nash

   Leading Article 16 September 2012 Pages: 11 - 17

3. The Impact of Managed Care on Clinical Research

   • Martin McKee
   • Elias Mossialos

   Leading Article 16 September 2012 Pages: 19 - 25

4. Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults

   • Adalsteinn D. Brown
   • Alan M. Garber

   Review Article 16 September 2012 Pages: 27 - 48

5. The Economics of Trace

   • Claude LePen
   • Hervé Lilliu
   • Sylvie Fiessinger

   Original Research Article 16 September 2012 Pages: 49 - 58

6. The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients

   • Michael J. Koren
   • Dean G. Smith
   • Donald M. Black

   Original Research Article 16 September 2012 Pages: 59 - 70

7. A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information

   • Robert S. Woodward
   • Leah Amir
   • Daniel C. Brennan

   Original Research Article 16 September 2012 Pages: 71 - 77

8. The Use of Decision-Analytical Modelling in Economic Evaluation of Patch Testing in Allergic Contact Dermatitis

   • Rukmini Rajagopalan
   • Roger T. Anderson
   • John Jones

   Original Research Article 16 September 2012 Pages: 79 - 95

9. Risperidone

   • Rachel H. Foster
   • Karen L. Goa

   Adis Pharmacoeconomic Drug Evaluation 16 September 2012 Pages: 97 - 133

10. ‘The Pros and Cons of a Single Euro-Price for Drugs’ and ‘The Economics of Parallel Trade’

    • Joan Rovira

    Correspondence 16 September 2012 Pages: 135 - 135

11. The authors’ reply

    • Patricia Danzon
    • Adrian Towse

    Correspondence 16 September 2012 Pages: 135 - 138